Tesla's Autonomous Ride-Hailing Expansion
This carefully selected group of stocks represents companies powering Tesla's ambitious robotaxi rollout in the Bay Area and Arizona. Professional analysts have identified these technology providers as essential to the autonomous driving supply chain, from semiconductors to sensors.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
NVIDIA Corporation
NVDA
Current price
$175.64
A leader in AI and high-performance computing, providing the core processing power (GPUs) essential for training and operating autonomous driving mode...
A leader in AI and high-performance computing, providing the core processing power (GPUs) essential for training and operating autonomous driving models.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Tesla's robotaxi expansion marks a pivotal shift from R&D to commercial deployment in autonomous driving. This creates sustained demand for companies providing the essential technology infrastructure, from high-performance computing to sensors and software platforms that make self-driving vehicles possible.
What You Need to Know
This collection spans the entire autonomous vehicle technology value chain. It includes market leaders in GPUs, advanced driver-assistance systems, automotive semiconductors, LiDAR, and sensor technologies. These companies stand to benefit as the autonomous vehicle industry enters its commercial phase.
Why These Stocks
These companies were handpicked because they provide critical components that enable the autonomous driving revolution. The portfolio balances pure-play autonomous driving technology providers with diversified tech companies that have significant exposure to this growing market.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+115.84%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 115.84% over the next year.
Stocks Rated Buy by Analysts
12 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Riding the Robotaxi Wave
Tesla's expansion validates the entire autonomous vehicle market, potentially accelerating adoption and creating a ripple effect of demand for all the critical technology providers in this collection.
From Testing to Revenue
The autonomous vehicle industry is shifting from R&D to commercial deployment, which means these companies could see growing, sustainable demand for their technologies after years of development.
Powering the Autonomous Future
These aren't just automotive stocks—they're technology innovators creating the building blocks for a transportation revolution that extends beyond Tesla to the entire mobility ecosystem.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.